Clinical Profile of MDR-TB patients with special reference to kanamycin induced ototoxicity in a tertiary care hospital of eastern India
Abstract
Introduction: MDR-TB is defined as resistance to isoniazid and rifampicin, with or without resistance to other anti-TB drugs. Multidrug-resistant TB (MDR-TB) remains a public health crisis and a health security threat. Kanamycin, is an aminoglycoside antibiotic used to treat multi-drug resistant TB in the intensive phase.
Objective: To analyze the patients of MDR-TB with respect to age, sex and presence of comorbidities like diabetes mellitus. Also to study the incidence of hearing impairments among patients of MDR-TB receiving injectable Kanamycin.
Methods: 40 patients of MDR-TB diagnosed by sputum culture and drug susceptibility testing (DST) have been classified on the basis of age, sex and presence of diabetes mellitus. All have received injectable Kanamycin for 6months in their intensive phase (IP). Patients giving history of auditory impairments underwent pure tone audiometry (PTA) for detection of sensory neural hearing loss, if any.
Result: Out of 40 patients of MDR-TB, 30 were males and the rest 10 were females. Age ranges from 12 to 70 years among which maximum patients fell in the age group of 21-30 years (12 patients). 16 patients were diabetic. After getting Kanamycin, 8 patients gave the history of auditory disturbances and only 1 patient found to have severe sensory neural hearing loss confirmed by pure tone audiometry.
Conclusion: Prevalence of MDR-TB has been found more among males and in younger age group. Diabetes Mellitus play a major role here. Kanamycin induced hearing loss is not a very serious concern in our study.
Downloads
References
Dodd P et al. Global burden of drug-resistant tuberculosis in children: a mathematical modelling study, The Lancet Infectious Diseases 2016;16(10):1193-1201, OCTOBER 01,2016,
World Health Organisation. Tuberculosis. 18 September. 2018
Prasad R, Verma SK, Sahai S, et al. Efficacy and safety of kanamycin, ethionamide, PAS and cycloserine in multidrug-resistant pulmonary tuberculosis patients. Indian J Chest Dis Allied Sci. 2006 Jul-Sep;48(3):183-6.
Caminero JA, Sotgiu G, Zumla A, et al. Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis. Lancet Infect Dis. 2010 Sep;10(9):621-9. doi: https://doi.org/10.1016/S1473-3099(10)70139-0.
Guidelines on programmatic management of drug-resistant Tuberculosis in India, 2017- Chapter7/ table 7.5/ page 71.
Walker HK, Hall WD, Hurst JW, et al. Clinical Methods: The History, Physical, and Laboratory Examinations.
Pei-Hua Chuang et al. Population-Based Drug Resistance Surveillance of Multidrug-Resistant Tuberculosis in Taiwan, 2007-2014.PLoS One. 2016 Nov 15;11(11):e0165222. doi: https://doi.org/10.1371/journal.pone.0165222. eCollection 2016
Hudelson P. Gender differentials in tuberculosis: the role of socio-economic and cultural factors. Tuber Lung Dis. 1996 Oct;77(5):391-400.
Katherine C. Horton et al. Sex Differences in Tuberculosis Burden and Notifications in Low- and Middle-Income Countries: A Systematic Review and Meta-analysis. PLoS Med. 2016 Sep 6;13(9):e1002119. doi: https://doi.org/10.1371/journal.pmed.1002119. eCollection 2016 Sep. Review.
Barach J. Historical facts in diabetes mellitus. Ann Med Hist. 1928;10:387.
Root H. The association of diabetes and tuberculosis. N Engl J Med. 1934;210:1, 78, 127.
Boucot KR, Dillon ES, Cooper DA, Meier P, et al. Tuberculosis among diabetics: the Philadelphia survey. Am Rev Tuberc. 1952 Jan;65(1:2):1-50.
Liu Q, Li W, Xue M, et al. Diabetes mellitus and the risk of multidrug resistant tuberculosis: a meta-analysis. Sci Rep. 2017 Apr 24;7(1):1090. doi: https://doi.org/10.1038/s41598-017-01213-5.
Balewgizie Sileshi Tegegne et al. Association between diabetes mellitus and multi-drug-resistant tuberculosis: a protocol for a systematic review and meta-analysis. Syst Rev. 2017; 6: 6.
Hong H, Budhathoki C, Farley JE. Increased risk of aminoglycoside-induced hearing loss in MDR-TB patients with HIV coinfection. Int J Tuberc Lung Dis. 2018 Jun 1;22(6):667-674. doi: https://doi.org/10.5588/ijtld.17.0830.
Joseph Satalof, Seymour Wagner, Hyman Menduke,. Kanamycin Ototoxicity in Healthy Men. Arch Otolaryngol. 1964;80(4):413-417. doi: https://doi.org/10.1001/archotol.1964.00750040425010.
Scott K. Heysell, Shahriar Ahmed, Md. Toufiq Rahman, et al. Hearing loss with kanamycin treatment for multidrug-resistant tuberculosis in Bangladesh. Eur Respir J. 2018 Mar; 51(3): 1701778. Published online 2018 Mar 22. doi: https://doi.org/10.1183/13993003.01778-2017
OAI - Open Archives Initiative
